| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2014-11-10 | Ambit Biosciences (USA - CA) | Daiichi Sankyo (Japan) | up to $410 million (€321.4 million) | Cancer - Oncology Autoimmune diseases Inflammatory diseases |
| 2014-11-07 | Kremers Urban, UCB\'s US specialty generics business (USA - IN, Belgium) | Advent International (USA - MA) Avista Capital Partners (USA - NY) | $ 1.525 billion | Generics |
| 2014-11-05 | CorQuest Medical (USA - Fl) | Cardio3 BioSciences (Belgium) | undisclosed | |
| 2014-11-04 | Definiens (Germany) | MedImmune (USA - global biologics arm of AstraZeneca (UK) | $150 million and additional predetermined milestone payments | Cancer - Oncology Technology - Services |
| 2014-11-03 | Dihon Pharmaceutical (China) | Bayer (Germany) | € 460 million | OTC |
| 2014-11-03 | Almirall’s respiratory franchise (Spain) | AstraZeneca (UK) | up to $1.22 billion | Respiratory diseases |
| 2014-11-03 | Galecto Biotech (Sweden) | BMS (USA - NY) | up to $444 million | Rare diseases |
| 2014-11-03 | Covance (USA - NJ) | Labcorp (USA - NC) | $5.6 billion (€4.47 million) | CRO Technology - Services |
| 2014-10-30 | Transcept Pharmaceuticals (USA - CA) | Paratek Pharmaceuticals (USA - MA) | Infectious diseases Neurosciences |
|
| 2014-10-28 | F-star Alpha (UK) | BMS (USA - NY) | up to $ 475million | |
| 2014-10-27 | Aciex Therapeutics (USA - MA) | Nicox (France) | Ophtalmological diseases |
|
| 2014-10-20 | Shire (UK - USA) | Abbvie (USA - IL) | £32 billion ($53 billion - € 40.5 billion) | Rares diseases CNS diseases Gastrointestinal diseases |
| 2014-10-10 | Auxilium Pharmaceuticals (USA - PA) | Endo International (Ireland) | $2.6 billion | Men's health Pain |
| 2014-10-09 | Tower Holdings, Lineage Therapeutics (USA - PA) | Impax Laboratories (USA - CA) | $700 million | |
| 2014-10-06 | Durata Therapeutics (USA - IL) | Actavis (USA - NJ) | $675 million | Infectious diseases |
| 2014-10-03 | Cosmo Pharmaceuticals (Italy) Cosmo Technologies (Ireland) | Salix Pharmaceuticals (USA - NC) | Gastrointestinal diseases |
|
| 2014-10-03 | Cell Marque Corporation (USA - CA) | Sigma-Aldrich (USA - MO) | undisclosed | Technology - Services Immunochemistry |
| 2014-10-03 | Immutep (France) | Prima BioMed (Australia) | $ 28 million (€ 22.1 million) | Cancer - Oncology Immunotherapy |
| 2014-10-02 | Pharmachem Technologies (Grand Bahama), a Novasep subsidiary (France) | undisclosed loval investor | undisclosed | Manufacturing Production |
| 2014-10-02 | BioChromix NewCo (Sweden) | Cadila Pharmaceuticals (India) | undisclosed | Neurodegenerative diseases |
